Dr Gerds on the Importance of Evaluating Selinexor in JAK In

Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.

Related Keywords

Aaron Gerds , Cleveland Clinic Taussig Cancer Institute , Medical Oncology , Reviewing Research Efforts Seeking To Raise The Bar In Myelofibrosis , Onclive Tv , Video , Expovio , Cleveland Clinic , Nct04562389 , Myelofibrosis , Selinexor , Phase 1 3 Xport Mf 034 Trial ,